Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Mitzi Miranda

Mitzi Miranda

Coordinator, Gyn/Onc Clinical Research Program

Cancer Center Division

Collaboration(5)

Setsuko Chambers
Carolyn Lane
Aradhana Kari
Angelique Thornton
Sonja Velickovic

Grants(5)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu
Active·2023·$0 / $560.9K·
External
ovarian cancer, combination therapy, platinum-resistant, peritoneal cancer, fallopian-tube cancer
Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate
Active·2023·$0 / $419.4K·
External
chemotherapy, antibody-drug conjugate, ovarian cancer, clinical trial, folate receptor
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
Active·2023·$0 / $270.2K·
External
clinical trials, cancer treatment, immunotherapy, chemotherapy, women's health
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platnum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive
2023·$0 / $217.6K·
External
cancer therapy, clinical trial, pharmacology, immunotherapy, drug development
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZNc3 in Combination with Niraparib in Subjects with Platinum Resistant Ovarian Cancer
2023·$0 / $18.4K·
External
ovarian cancer, combination therapy, dose escalation, dose expansion, platinum-resistant